Clinical Trial Update: Alemtuzumab and Pentostatin In T-cell Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alemtuzumab in combination with pentostatin for T-cell neoplasms was terminated; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Pentostatin (pentostatin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma, Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2011-03-28